**Metastatic**

- **HER2 +**
  - **3rd Line or Later**
    - **BRS0131**
      - Phase I/II IV Zotatifin (eFT226) in Selected Advanced Solid Tumor Malignancies
      - PI: Caswell-Jin
      - Sponsor: eFFECTOR Therapeutics, Inc.
      - Priority 1
  - **BRS0115**
    - Expanded Access Pertuzumab & Trastuzumab Fixed-Dose Combo in HER2+ Breast Cancer During COVID-19 Pandemic
    - PI: Riaz
    - Sponsor: Genentech
  - **BRS0142**
    - Phase I/II Open Label Dose Escalation and Dose Expansion Study to Evaluate Safety, Tolerability, Dosimetry, and Preliminary Efficacy of HER2 Directed Radioligand CAM-H2 in Advanced/Metastatic HER2-Positive Breast, Gastric, & Gastro-Esophageal Junction Cancer
    - PI: Aparici
    - Sponsor: Precirix NV

**KEY**
- Waiting
- Open for Enrollment
- Observational Study
- Optional Path
- Trial Posting
- Extension Study
- Immunotherapy

*Please mark up a copy using black ink and email changes to SRC-office@stanford.edu*